|Age:||18 to 75 years old|
|Keywords:||PBC, Primary Biliary Cholangitis, Seladelpar|
|Type:||Drug study, Phase 3|
There will be a total of approximately 13 study visits over a period of approximately 60 weeks (about 1 year and 2 months).
If you qualify to participate in this study, you will be randomized (by chance, like a flip of a coin) to one of three treatment groups. You will have a 2 in 3 chance of receiving the study drug and a 1 in 3 chance of receiving placebo.
Open Label Study: At the end of this study all study participants can rollover to the open label study. This means that all participants will receive the study drug, seladelpar. The open label study will have visits every 3 months and will last up to 3 years.
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.